Bupropion for treatment of interferon-induced depression

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1202-1205

  Malek Ahmadi, Parviz ^a   Ghandour, Elias ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Bupropion, sustained release; Depression; Hepatitis C; Interferon alfa

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; INTERFERON; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RECURRENCE RISK; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; SUSTAINED DRUG RELEASE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIVIRAL AGENTS; BUPROPION; DEPRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B;

EID: 3042694251     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D516     Document Type: Article

References (25)

1. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11.
2. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993;88:760-1.
3. Goldman SL. Successful treatment of interferon-alfa-induced depression treated with nortriptyline (letter). Psychosomatics 1994;35:412-3.
4. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999;40:510-2.
5. Schramm TM, Lawford BR, Macdonald GA, Cooksley WGE. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-61.
6. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9.
7. Farah A. Interferon-induced depression treated with citalopram (letter). J Clin Psychiatry 2002;63:166-7.
8. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000;54: 565-72.
9. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-20.
10. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
11. Beck AT, Steer RA, Brown GK. BDI-II Manual. San Antonio, TX: Harcourt Brace, The Psychological Corporation, 1996.
12. Antidepressants. In: Schatzberg AF, Cole JO, DeBattista C, eds. Manual of clinical psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing Inc., 2003:37-157.
13. Chronic hepatitis C: current disease management. Bethesda, MD: National Digestive Diseases Information Clearinghouse, December 2003.
14. Prior TI, Chue PS. Psychotic depression occurring after stopping interferon-α (letter). J Clin Psychopharmacol 1999;19:385-6.
15. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123: 897-903.
16. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl J Med 1998;339:1493-9.
17. Quitkin FM, McGrath PJ, Stewart JW, Ocepek-Welikson K, Taylor BP, Nunes E, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53: 785-92.
18. Somatic treatments. In: Andreasen NC, Black DW, eds. Introductory textbook of psychiatry. 3rd ed. Washington, DC: American Psychiatric Publishing Inc., 2001:709-59.
19. Van Thiel DH, Fiedlander L, De Maria N, Molloy PJ, Kania RJ, Colantoni A. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepato Gastroenterol 1998;45: 328-30.
20. Loftis JM, Hauser P. Comanagement of depression and HCV treatment. Psychiatric Ann 2003;33:385-91.
21. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of serotonin transporter. Eur J Pharmacol 1998;349:317-24.
22. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T. Effect of a single intraventricular injection of α-interferon on monoamine concentrations in the rat brain. Eur J Neuropsychopharmacol 2000;10:129-32.
23. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta 1989;1012:140-7.
24. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22: 86-90.
25. Biological therapies. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's synopsis of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2003:974-1150.